AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27930386 — intervention group
Group type: EXPERIMENTAL
Intervention: GCSF 300 μg twice daily for 5 days plus standard medical therapy (SMT)
Number of subjects: 253
Study 27930386 — intervention group
Group type: COMPARATOR
Intervention: SMT alone
Number of subjects: 253
Study 25413483 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion technique
Number of subjects: 1005
Study 25413483 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap-fitted colonoscopy
Number of subjects: 1005
Study 25413483 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 1005
Study 27341466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) at 70% of maximum protrusion and 4 mm of vertical opening
Number of subjects: 72
Study 27341466 — intervention group
Group type: COMPARATOR
Intervention: Mandibular advancement splint (MAS) at 60% of maximum protrusion and 4 mm of vertical opening
Number of subjects: 72
Study 27341466 — intervention group
Group type: COMPARATOR
Intervention: Mandibular advancement splint (MAS) at 60% of maximum protrusion and 6 mm of vertical opening
Number of subjects: 72
Study 27341466 — intervention group
Group type: COMPARATOR
Intervention: Mandibular advancement splint (MAS) at 70% of maximum protrusion and 6 mm of vertical opening
Number of subjects: 72
Study 23778091 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 36
Study 23778091 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized LASIK
Number of subjects: 36
Study 21787219 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconitum napellus (30c potency)
Number of subjects: 77
Study 21787219 — intervention group
Group type: EXPERIMENTAL
Intervention: Aconitum napellus (1M potency)
Number of subjects: 77
Study 21787219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphur (200c and 1M potency)
Number of subjects: 77
Study 21787219 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelsemium (200c potency)
Number of subjects: 77
Study 21787219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatilla (200c potency)
Number of subjects: 77
Study 21787219 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelsemium (1M potency)
Number of subjects: 77
Study 21787219 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus (1M potency)
Number of subjects: 77
Study 21787219 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphur (1M potency)
Number of subjects: 77
Study 21787219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 19512981 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily
Number of subjects: 32
Study 19512981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16460630 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 41
Study 16460630 — intervention group
Group type: COMPARATOR
Intervention: Alcohol gel
Number of subjects: 41
Study 15302456 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliomolar Radiopaque (HR)
Number of subjects: 4
Study 15302456 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetric Ceram (TC)
Number of subjects: 4
Study 15302456 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z250 (FZ)
Number of subjects: 4
Study 15302456 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodigy Condensable (PR)
Number of subjects: 4
Study 15302456 — intervention group
Group type: COMPARATOR
Intervention: All materials tested
Number of subjects: 4
Study 11404722 — intervention group
Group type: COMPARATOR
Intervention: OAC7 (Omeprazole 20 mg b.i.d., Amoxycillin 1 g, Clarithromycin 500 mg)
Number of subjects: 325
Study 11404722 — intervention group
Group type: COMPARATOR
Intervention: OAM7 (Omeprazole 20 mg b.i.d., Amoxycillin 1 g, Metronidazole 500 mg)
Number of subjects: 325
Study 11404722 — intervention group
Group type: EXPERIMENTAL
Intervention: OTA7 (Omeprazole 20 mg b.i.d., Tetracycline 500 mg t.i.d., Amoxycillin 1 g b.i.d.)
Number of subjects: 325
Study 10421667 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2b + placebo (monotherapy)
Number of subjects: 324
Study 10421667 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b + ribavirin (combination therapy)
Number of subjects: 324
Study 10155073 — intervention group
Group type: EXPERIMENTAL
Intervention: Voda guiding catheter
Number of subjects: 40
Study 10155073 — intervention group
Group type: COMPARATOR
Intervention: Amplatz guiding catheter
Number of subjects: 40
Study 2750673 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (2.5 mg/day, adjusted to lower VIIc to 70% of standard and increase prothrombin time INR to 1.6)
Number of subjects: 6000
Study 2750673 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same dose sequence as warfarin)
Number of subjects: 6000
Study 2750673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (low-dose warfarin and low-dose aspirin 75 mg/day)
Number of subjects: 6000
Study 835781 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) chemotherapy
Number of subjects: 274
Study 835781 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) chemotherapy to the point of toxicity
Number of subjects: 274
Study 835781 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 274
Study 30526183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented UKA
Number of subjects: 80
Study 30526183 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless UKA
Number of subjects: 80
Study 28339139 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 33224
Study 28339139 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 33224
Study 26280587 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led, culturally specific, faith-based program to increase physical activity
Number of subjects: 0
Study 23232805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxifluridine (800 mg/m2/day) in 3 divided doses
Number of subjects: 100
Study 23232805 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral uracil/tegafur (UFT) (400 mg/m2/day) in 2 divided doses
Number of subjects: 100
Study 23232805 — intervention group
Group type: COMPARATOR
Intervention: Doxifluridine group
Number of subjects: 100
Study 21646066 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mobilisation after Angio-Seal™ deployment
Number of subjects: 300
Study 21646066 — intervention group
Group type: COMPARATOR
Intervention: Delayed ambulation
Number of subjects: 300
Study 21646066 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation cohort (standard-care)
Number of subjects: 300
Study 19671372 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mometasone 50 micrograms in each nostril once daily for 3 months
Number of subjects: 217
Study 19671372 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray once daily for 3 months
Number of subjects: 217
Study 19671372 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mometasone
Number of subjects: 217
Study 19671372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 17057920 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (600 mg three times a day, started 30-56 hours before surgery)
Number of subjects: 93
Study 17057920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 17057920 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 93
Study 15684785 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic ultrasound training
Number of subjects: 28
Study 11225504 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual and group Cognitive Behavioral Therapy (CBT) and family anxiety management training
Number of subjects: 0
Study 11225504 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors, buspirone, and high‐potency benzodiazepines
Number of subjects: 0
Study 11225504 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy, pharmacotherapy, and both
Number of subjects: 0
Study 9286523 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RM-GIC)
Number of subjects: 40
Study 9286523 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 40
Study 9433396 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg CGP 51901
Number of subjects: 153
Study 9433396 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg CGP 51901
Number of subjects: 153
Study 9433396 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg CGP 51901
Number of subjects: 153
Study 9433396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 2667509 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 25
Study 2667509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 785442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflucortolone valerianate, 0.1%
Number of subjects: 52
Study 785442 — intervention group
Group type: COMPARATOR
Intervention: Flumethasone pivalate, 0.02%
Number of subjects: 52
Study 31794072 — intervention group
Group type: EXPERIMENTAL
Intervention: SM-1 (a combination of diphenhydramine, zolpidem delayed release, and lorazepam delayed release)
Number of subjects: 0
Study 31794072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31794072 — intervention group
Group type: EXPERIMENTAL
Intervention: SM-1
Number of subjects: 0
Study 28861651 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Responsive Teaching (ART)
Number of subjects: 87
Study 28861651 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 25512454 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 7576
Study 25512454 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 7576
Study 23127290 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance cognitive behavior therapy (M-CBT)
Number of subjects: 379
Study 23127290 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (control)
Number of subjects: 379
Study 23127290 — intervention group
Group type: EXPERIMENTAL
Intervention: M-CBT
Number of subjects: 379
Study 23127290 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual symptoms of agoraphobia at the end of acute-phase treatment
Number of subjects: 379
Study 22103994 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical algorithm for HIV presumptive diagnosis
Number of subjects: 542
Study 22103994 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical findings (oral thrush, hepatomegaly, lymphadenopathy, etc.)
Number of subjects: 542
Study 22103994 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual clinical signs
Number of subjects: 542
Study 22103994 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical algorithm
Number of subjects: 542
Study 18925985 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 Hz rTMS treatment
Number of subjects: 34
Study 18925985 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 34
Study 16968234 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg iron orally twice a day for 3 months
Number of subjects: 50
Study 16968234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15140310 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered commercial 1% xylocaine (with 1:200,000 adrenaline)
Number of subjects: 85
Study 15140310 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered commercial 1% xylocaine (with 1:200,000 adrenaline)
Number of subjects: 85
Study 11524329 — intervention group
Group type: EXPERIMENTAL
Intervention: small‐dose nalbuphine (0.2 microg/mL)
Number of subjects: 8
Study 11524329 — intervention group
Group type: EXPERIMENTAL
Intervention: large‐dose nalbuphine (0.4 microg/mL)
Number of subjects: 8
Study 11524329 — intervention group
Group type: EXPERIMENTAL
Intervention: atropine (1‐mg bolus and 0.5 mg/h)
Number of subjects: 8
Study 11524329 — intervention group
Group type: COMPARATOR
Intervention: control (no drug)
Number of subjects: 8
Study 9263382 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug A (antidepressant immediate-release product)
Number of subjects: 10
Study 9263382 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug B (antiepileptic controlled release product)
Number of subjects: 10
Study 8348164 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG therapy
Number of subjects: 61
Study 8348164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 8348164 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 61
Study 3534852 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg t.i.d.
Number of subjects: 94
Study 3534852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 29888944 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking-aloud nominal group
Number of subjects: 156
Study 29888944 — intervention group
Group type: EXPERIMENTAL
Intervention: Interacting groups
Number of subjects: 156
Study 29888944 — intervention group
Group type: COMPARATOR
Intervention: Quiet nominal group
Number of subjects: 156
Study 26916033 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Cognitive Counseling (PCC)
Number of subjects: 0
Study 24275453 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory and expiratory muscle training (Threshold Inspiratory Muscle Trainer and Threshold Positive Expiratory Pressure) for 15 minutes each, twice a day, five days/week for eight weeks
Number of subjects: 26
Study 24275453 — intervention group
Group type: COMPARATOR
Intervention: Sham group with lowest loads for training
Number of subjects: 26
Study 22773209 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib plus lenalidomide/thalidomide
Number of subjects: 1200
Study 22773209 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib or lenalidomide/thalidomide
Number of subjects: 1200
Study 20056391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT)
Number of subjects: 85
Study 20056391 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 85
Study 17723312 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative emotional priming
Number of subjects: 120
Study 17723312 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive emotional priming
Number of subjects: 120
Study 17723312 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral emotional priming
Number of subjects: 120
Study 17723312 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-related pictures
Number of subjects: 120
Study 17723312 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatoform pain disorder
Number of subjects: 120
Study 17723312 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia
Number of subjects: 120
Study 17723312 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure pain sensitivity
Number of subjects: 120
Study 15709984 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment with a proton pump inhibitor
Number of subjects: 773
Study 15709984 — intervention group
Group type: COMPARATOR
Intervention: No pre-treatment with a proton pump inhibitor
Number of subjects: 773
Study 12029512 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ESWT (3 x 2000 pulses, energy flux density ED(+) 0.04 to 0.22 mJ/mm(2) under local anaesthesia)
Number of subjects: 272
Study 12029512 — intervention group
Group type: COMPARATOR
Intervention: Placebo ESWT
Number of subjects: 272
Study 10509497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 parts per million (ppm) inhaled nitric oxide
Number of subjects: 204
Study 10509497 — intervention group
Group type: COMPARATOR
Intervention: Control ventilation therapy without nitric oxide
Number of subjects: 204
Study 7574002 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22
Study 7574002 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 22
Study 7574002 — intervention group
Group type: COMPARATOR
Intervention: Control Drama (Neutral)
Number of subjects: 22
Study 1942779 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 liter of 0.9% saline administered i.v. over one hour prior to amphotericin B
Number of subjects: 20
Study 1942779 — intervention group
Group type: COMPARATOR
Intervention: 1 liter of 5% dextrose in water administered i.v. over one hour prior to amphotericin B
Number of subjects: 20
Study 1942779 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 6292981 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg)
Number of subjects: 8
Study 6292981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30353619 — intervention group
Group type: EXPERIMENTAL
Intervention: linaclotide 0.5 mg
Number of subjects: 186
Study 30353619 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 186
Study 27586134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 247
Study 27586134 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 247
Study 27586134 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity physical activity
Number of subjects: 247
Study 26639039 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c <6.5%
Number of subjects: 1145
Study 26639039 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c 6.5% to 8.5%
Number of subjects: 1145
Study 26639039 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c >8.5%
Number of subjects: 1145
Study 26639039 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin reaction units >550
Number of subjects: 1145
Study 25127483 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5145
Study 25127483 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5145
Study 22219246 — intervention group
Group type: EXPERIMENTAL
Intervention: Piriformis-sparing approach
Number of subjects: 100
Study 22219246 — intervention group
Group type: COMPARATOR
Intervention: Standard posterior approach
Number of subjects: 100
Study 19683936 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (ADO) pretreatment (10‐min 100 microgkg(‐1)min(‐1) ADO) before application of the aortic cross‐clamp and antegrade 1 mmol l(‐1) adenosine high‐potassium ([K(+)]=20 mol l(‐1)) cold blood cardioplegia
Number of subjects: 30
Study 19683936 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) received antegrade cold (12 degrees C) high‐potassium ([K(+)]=20 mol l(‐1)) institute blood cardioplegia
Number of subjects: 30
Study 17257464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol/THC buccal spray
Number of subjects: 298
Study 17257464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 298
Study 17257464 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 298
Study 17257464 — intervention group
Group type: EXPERIMENTAL
Intervention: All cannabinoids pooled together
Number of subjects: 298
Study 17257464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 17257464 — intervention group
Group type: COMPARATOR
Intervention: Cannabinoids vs Placebo
Number of subjects: 298
Study 15023508 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated group therapy (IGT)
Number of subjects: 45
Study 15023508 — intervention group
Group type: COMPARATOR
Intervention: No intervention (no IGT)
Number of subjects: 45
Study 15023508 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 45
Study 11464374 — intervention group
Group type: EXPERIMENTAL
Intervention: No bed rest (Group N)
Number of subjects: 38
Study 11464374 — intervention group
Group type: COMPARATOR
Intervention: Bed rest (Group L)
Number of subjects: 38
Study 9581366 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health awareness campaign (test group)
Number of subjects: 98
Study 9581366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 98
Study 8067402 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) 50 micrograms over 3 min, then 50 ng.kg‐1.min‐1
Number of subjects: 6
Study 8067402 — intervention group
Group type: COMPARATOR
Intervention: Saline (vehicle)
Number of subjects: 6
Study 2661155 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 100
Study 2661155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 4556543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergot alkaloid (2-Br-alpha-ergocryptine; ergocryptine; CB 154)
Number of subjects: 60
Study 4556543 — intervention group
Group type: EXPERIMENTAL
Intervention: Stilboestrol
Number of subjects: 60
Study 4556543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31371165 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-based adjustment (SBA) with as-needed beclomethasone 80 μg and rescue short-acting β-agonist
Number of subjects: 206
Study 31371165 — intervention group
Group type: COMPARATOR
Intervention: Provider-based guideline-directed adjustment (PBA) with maintenance beclomethasone 80 μg/d (6-11 years) or 160 μg/d (12-17 years)
Number of subjects: 206
Study 29337780 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate/magnesium citrate
Number of subjects: 341
Study 29337780 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid-enriched polyethylene glycol solution plus bisacodyl
Number of subjects: 341
Study 29337780 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 341
Study 28094466 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 2244
Study 28094466 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive medical therapy alone for CHD with β-blockers
Number of subjects: 2244
Study 28094466 — intervention group
Group type: EXPERIMENTAL
Intervention: Early revascularization for CHD with β-blockers
Number of subjects: 2244
Study 28094466 — intervention group
Group type: COMPARATOR
Intervention: No β-blockers
Number of subjects: 2244
Study 26154249 — intervention group
Group type: EXPERIMENTAL
Intervention: Directed self‐regulated learning (DSRL)
Number of subjects: 40